Sitagliptin

Sitagliptin is a DPP‑4 inhibitor with modest HbA1c reduction and cardiovascular neutrality; it has no demonstrated heart failure outcome benefit. DPP-4 inhibitors may in fact exacerbate heart failure symptoms through oedema worsening. This is not the best drug for Mr. Green.

Please go back and re-consider. 

  • Lab coat may transfer hazardous materials to the outside general area and contaminate the area [undo]
  • Option 3 [undo]
  • Semaglutide [undo]
  • Cystic Fibrosis: Setting the Scene [undo]
  • Dapagliflozin [undo]
  • Συνταγογράφηση αντιβίωσης και παυσιπόνου φαρμάκου καθώς και καραμέλες για τον πονόλαιμο. [undo]
  • Sitagliptin [undo]

Map: Michael Green_GEMD_1 (1115)
Node: 21101
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway